• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA Grants Orphan Drug Status to ApoGraft for Acute and Chronic GvHD americanpharmaceuticacreview
    September 06, 2017
    Cellect Biotechnology announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cellect's ApoGraft for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service